Novo Nordisk forms cardiometabolic drug discovery accelerator to get to research faster

No­vo Nordisk is now tap­ping in­to ear­li­er stages of car­diometa­bol­ic re­search by bring­ing to­geth­er aca­d­e­m­ic in­sti­tu­tions and Ger­man drug dis­cov­ery shop Evotec af­ter it bought a cou­ple of star­tups and inked mul­ti­ple biotech col­lab­o­ra­tions this sum­mer.

Fol­low­ing a chron­ic kid­ney dis­ease tie-up in 2020, the Dan­ish Big Phar­ma and Evotec are com­ing to­geth­er again to form a trans­la­tion­al drug dis­cov­ery ac­cel­er­a­tor dubbed LAB eN². It’s named af­ter the com­pa­nies’ ini­tials and based out of No­vo’s Bio In­no­va­tion Hub in Cam­bridge, MA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.